Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole.
OBJECTIVE
Rabeprazole has a faster onset of antisecretory activity than omeprazole and lansoprazole. The aim of the present study was to clarify whether there is any difference in the speed of symptom relief in patients with reflux esophagitis following the administration of these three proton pump inhibitors (PPI).


METHODS
Eighty-five patients with erosive reflux esophagitis were randomized to receive 8 weeks of 20 mg of omeprazole (n = 30), 30 mg of lansoprazole (n = 25), or 20 mg of rabeprazole (n = 30) once a morning. Daily changes in heartburn and acid reflux symptoms in the first 7 days of administration were assessed using a six-point scale (0: none, 1: mild, 2: mild-moderate, 3: moderate, 4: moderate-severe, 5: severe).


RESULTS
The mean heartburn score in patients administered rabeprazole decreased more rapidly than those given the other PPI. Complete heartburn remission also occurred more rapidly in patients administered rabeprazole (compared with omeprazole: P = 0.035, compared with lansoprazole: P = 0.038 by log-rank test). No differences were seen in the rate of endoscopic healing of reflux esophagitis at 8 weeks between the three treatment regimens.


CONCLUSIONS
Rabeprazole may be more effective than omeprazole and lansoprazole for the rapid relief of heartburn symptoms in patients with reflux esophagitis.
Adachi
Kyoichi
K
Department of Internal Medicine II, Shimane Medical University, Department of Internal Medicine, Unnan General Hospital, Shimane, Japan. kadachi@shimane-med.ac.jp
Hashimoto
Tomoyuki
T
Hamamoto
Naoharu
N
Hirakawa
Kazuya
K
Niigaki
Masatoshi
M
Miyake
Tatsuya
T
Taniura
Hiroyuki
H
Ono
Masahiro
M
Kaji
Takekazu
T
Suetsugu
Hiroshi
H
Yagi
Junko
J
Komazawa
Yoshinori
Y
Mihara
Takafumi
T
Katsube
Tomoko
T
Fujishiro
Hirofumi
H
Shizuku
Toshihiro
T
Hattori
Shuzo
S
Yamamoto
Shun
S
Kinoshita
Yoshikazu
Y
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D004942:Esophagitis, Peptic / Q000150:complications*; D005260:Female; D006356:Heartburn / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011446:Prospective Studies; D054328:Proton Pump Inhibitors; D064750:Rabeprazole; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D064750:Rabeprazole; D009853:Omeprazole